Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

By Van Cutsem Eric  

Targeted Oncology, Vol. 3, Iss. 4, 2008-10 ,pp. : 223-225

Springer Publishing Company

Access to resources Recommend Favorite

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

By Sartore-Bianchi Andrea  

Targeted Oncology, Vol. 5, Iss. 1, 2010-03 ,pp. : 19-28

Springer Publishing Company

Access to resources Recommend Favorite

Association between codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis

By Chen Jian   Ye Yun   Sun Haozhen   Shi Genming  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 265-272

Springer Publishing Company

Access to resources Recommend Favorite

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

By Kishiki Tomokazu   Ohnishi Hiroaki   Masaki Tadahiko   Ohtsuka Kouki   Ohkura Yasuo   Furuse Jyunji   Watanabe Takashi   Sugiyama Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite